Philip R. Kym
AbbVie (United States) · 135 works · 5,864 citations · h-index 42
Top works
- Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
- A Novel Antiinflammatory Maintains Glucocorticoid Efficacy with Reduced Side Effects
- Targeting TRP channels for pain relief
- Validation of Diacyl Glycerolacyltransferase I as a Novel Target for the Treatment of Obesity and Dyslipidemia Using a Potent and Selective Small Molecule Inhibitor
- Design, Synthesis, and Conformational Analysis of a Proposed Type I β-Turn Mimic
- Selective blockade of TRPA1 channel attenuates pathological pain without altering noxious cold sensation or body temperature regulation
- Identification of 2-(4-Benzyloxyphenyl)-N- [1-(2-pyrrolidin-1-yl-ethyl)-1H-indazol-6-yl]acetamide, an Orally Efficacious Melanin-Concentrating Hormone Receptor 1 Antagonist for the Treatment of Obesity
- Discovery of Potent, Selective, Orally Bioavailable Stearoyl-CoA Desaturase 1 Inhibitors
- Nonsteroidal Selective Glucocorticoid Modulators: The Effect of C-10 Substitution on Receptor Selectivity and Functional Potency of 5-Allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano[3,4-f]quinolines
- The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity
- Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia
- Synthesis and Characterization of Non-Steroidal Ligands for the Glucocorticoid Receptor: Selective Quinoline Derivatives with Prednisolone-Equivalent Functional Activity
- TRPA1 Modulation of Spontaneous and Mechanically Evoked Firing of Spinal Neurons in Uninjured, Osteoarthritic, and Inflamed Rats
- Molecular Determinants of Species-Specific Activation or Blockade of TRPA1 Channels
- Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease
- Analgesic potential of TRPV1 antagonists
- The Pursuit of Differentiated Ligands for the Glucocorticoid Receptor
- Liver-Selective Glucocorticoid Antagonists: A Novel Treatment for Type 2 Diabetes
- Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity
- Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes